Expert review of anti-infective therapy · 2026
Efficacy and safety of gepotidacin versus standard of-care antibiotics for the treatment of uncomplicated urogenital infections in adults and adolescents: a systematic review and meta-analysis.
Систематический обзорСтатьяМетаанализСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reddy Mounika, Jain Vishakha, Eerike Madhavi, Reddy Manasa, Bisoi Debasis, Golla Vahini, Raj Gerard Marshall
Аннотация
BACKGROUND: Gepotidacin, a novel oral antibacterial targeting bacterial DNA gyrase and topoisomerase IV, exhibits potent activity against Escherichia coli and Neisseria gonorrhoeae resistant strains. This systematic review and meta-analysis assessed the efficacy and safety of gepotidacin compared with standard-of-care antibiotics in adults and adolescents with uncomplicated urogenital infections.
METHODS: Randomized controlled trials comparing gepotidacin with standard antibiotic regimens for uncomplicated urinary tract infections or urogenital gonorrhea were included. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for microbiological success, clinical cure, and serious adverse events (SAEs). Risk of bias and certainty of evidence were assessed using the Cochrane RoB2 tool and GRADE approach, respectively.
RESULTS: Three phase 3 trials (EAGLE-1, EAGLE-2, EAGLE-3; n = 3,757) were included. Gepotidacin achieved comparable microbiological success (RR = 1.10; 95% CI: 0.96-1.27; p = 0.17) and clinical cure rates (RR = 1.04; 95% CI: 0.95-1.13; p = 0.39) versus standard antibiotics. SAEs were rare and balanced (RR = 0.98; 95% CI: 0.37-2.58; p = 0.96). Overall risk of bias was low.
CONCLUSIONS: Gepotidacin demonstrates non-inferior efficacy and comparable safety to standard antibiotics, supporting its role as a promising oral agent against resistant E. coli and N. gonorrhoeae.
METHODS: Randomized controlled trials comparing gepotidacin with standard antibiotic regimens for uncomplicated urinary tract infections or urogenital gonorrhea were included. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated for microbiological success, clinical cure, and serious adverse events (SAEs). Risk of bias and certainty of evidence were assessed using the Cochrane RoB2 tool and GRADE approach, respectively.
RESULTS: Three phase 3 trials (EAGLE-1, EAGLE-2, EAGLE-3; n = 3,757) were included. Gepotidacin achieved comparable microbiological success (RR = 1.10; 95% CI: 0.96-1.27; p = 0.17) and clinical cure rates (RR = 1.04; 95% CI: 0.95-1.13; p = 0.39) versus standard antibiotics. SAEs were rare and balanced (RR = 0.98; 95% CI: 0.37-2.58; p = 0.96). Overall risk of bias was low.
CONCLUSIONS: Gepotidacin demonstrates non-inferior efficacy and comparable safety to standard antibiotics, supporting its role as a promising oral agent against resistant E. coli and N. gonorrhoeae.